Molecules of the Month

July 2022

An oral, brain penetrant EGFR mutant inhibitor with exquisite selectivity, a drug that was originally developed from a brain cholesterol metabolite, and a muscarinic antagonist and β2 agonist that was developed using soft drug design are some examples of this month's MOTM. In the slide deck, you'll also find a drug utilizing an N-oxide motif and a drug optimized to overcome aldehyde oxidase metabolism. Check out the ten molecule minireviews in the slide deck which covers:

  • Where are all of the Molecules of the Month in clinical development?

  • What's known about differentiation from previous molecules?

  • Where did the starting points come from?

  • Industry context, mechanism of action details, and more…

Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.